First ready-to-use toxin to launch
Pharmaceutical company Galderma has confirmed the first ready-to-use liquid neuromodulator has completed its European decentralised trial in Europe.
Pharmaceutical company Galderma has confirmed the first ready-to-use liquid neuromodulator has completed its European decentralised trial in Europe.
Following positive phase 2 results from its ready-to-use liquid formulation botulinum toxin, global pharmaceutical company Galderma has received a manufacturing license from the Swedish Medical Products Agency (MPA) for a new state-of-the-art manufacturing facility at the Center of Excellence, located in Uppsala, Sweden.